Fine-tuning front-line therapy in chronic lymphocytic leukemia News from ASH 2019

被引：1

作者：

Bohn, Jan-Paul ^{[1
]}

Wolf, Dominik ^{[1
]}

机构：

[1] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Anichstr 35, A-6020 Innsbruck, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2020年 / 13卷 / 03期

关键词：

First-line; Ibrutinib; Acalabrutinib; Venetoclax; Obinutuzumab; BRUTONS TYROSINE KINASE; ACALABRUTINIB ACP-196; INHIBITOR; VENETOCLAX; IBRUTINIB; CLL; APOPTOSIS; RITUXIMAB;

D O I：

10.1007/s12254-020-00615-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A deeper understanding of disease biology and the advent of targeted drugs have implemented chemotherapy-free treatment options in chronic lymphocytic leukemia (CLL). With consistently superior outcome data and good tolerability, the Bruton's kinase inhibitor ibrutinib as well as the B-cell lymphoma 2 inhibitor venetoclax +/- CD20 antibody have recently been licensed for first-line treatment independently of TP53 status and are currently recommended as therapy of choice in most patient subgroups according to international management guidelines. Survival curves, however, have not reached a plateau and relapse due to acquired resistance or drug intolerance remain major hurdles in CLL treatment. Clinical trials currently focus on the most promising combinations and sequences of highly effective targeted drugs aimed at avoiding drug resistance by further enhancing eradication of minimal residual disease and optimizing drug tolerability. This brief review provides an update on the recently presented clinical trial data in first-line CLL at ASH 2019 and discusses clinically relevant obstacles to overcome.

引用

页码：259 / 265

页数：7

共 31 条

[1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study [J].

Ahn, Inhye E. ;

Farooqui, Mohammed Z. H. ;

Tian, Xin ;

Valdez, Janet ;

Sun, Clare ;

Soto, Susan ;

Lotter, Jennifer ;

Housel, Stephanie ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Maric, Irina ;

Calvo, Katherine R. ;

Nierman, Pia ;

Hughes, Thomas E. ;

Saba, Nakhle S. ;

Marti, Gerald E. ;

Pittaluga, Stefania ;

Herman, Sarah E. M. ;

Niemann, Carsten U. ;

Pedersen, Lone B. ;

Geisler, Christian H. ;

Childs, Richard ;

Aue, Georg ;

Wiestner, Adrian .

BLOOD, 2018, 131 (21) :2357-2366

[2] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax [J].

Anderson, Mary Ann ;

Tam, Constantine ;

Lew, Thomas E. ;

Juneja, Surender ;

Juneja, Manu ;

Westerman, David ;

Wall, Meaghan ;

Lade, Stephen ;

Gorelik, Alexandra ;

Huang, David C. S. ;

Seymour, John F. ;

Roberts, Andrew W. .

BLOOD, 2017, 129 (25) :3362-3370

[3] Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile [J].

Barf, Tjeerd ;

Covey, Todd ;

Izumi, Raquel ;

van de Kar, Bas ;

Gulrajani, Michael ;

van Lith, Bart ;

van Hoek, Maaike ;

de Zwart, Edwin ;

Mittag, Diana ;

Demont, Dennis ;

Verkaik, Saskia ;

Krantz, Fanny ;

Pearson, Paul G. ;

Ulrich, Roger ;

Kaptein, Allard .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02) :240-252

[4] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results [J].

Byrd, John C. ;

Wierda, William G. ;

Schuh, Anna ;

Devereux, Stephen ;

Chaves, Jorge M. ;

Brown, Jennifer R. ;

Hillmen, Peter ;

Martin, Peter ;

Awan, Farrukh T. ;

Stephens, Deborah M. ;

Ghia, Paolo ;

Barrientos, Jacqueline ;

Pagel, John M. ;

Woyach, Jennifer A. ;

Burke, Kathleen ;

Covey, Todd ;

Gulrajani, Michael ;

Hamdy, Ahmed ;

Izumi, Raquel ;

Frigault, Melanie M. ;

Patel, Priti ;

Rothbaum, Wayne ;

Wang, Min Hui ;

O'Brien, Susan ;

Furman, Richard R. .

BLOOD, 2020, 135 (15) :1204-1213

[5] Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Harrington, Bonnie ;

O'Brien, Susan ;

Jones, Jeffrey A. ;

Schuh, Anna ;

Devereux, Steve ;

Chaves, Jorge ;

Wierda, William G. ;

Awan, Farrukh T. ;

Brown, Jennifer R. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Ghia, Paolo ;

Barrientos, Jacqueline C. ;

Pagel, John M. ;

Woyach, Jennifer ;

Johnson, Dave ;

Huang, Jane ;

Wang, Xiaolin ;

Kaptein, Allard ;

Lannutti, Brian J. ;

Covey, Todd ;

Fardis, Maria ;

McGreivy, Jesse ;

Hamdy, Ahmed ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Diacovo, Thomas G. ;

Johnson, Amy J. ;

Furman, Richard R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332

[6] miR-15 and miR-16 induce apoptosis by targeting BCL2 [J].

Cimmino, A ;

Calin, GA ;

Fabbri, M ;

Iorio, MV ;

Ferracin, M ;

Shimizu, M ;

Wojcik, SE ;

Aqeilan, RI ;

Zupo, S ;

Dono, M ;

Rassenti, L ;

Alder, H ;

Volinia, S ;

Liu, CG ;

Kipps, TJ ;

Negrini, M ;

Croce, CM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (39) :13944-13949

[7] Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia [J].

Deng, J. ;

Isik, E. ;

Fernandes, S. M. ;

Brown, J. R. ;

Letai, A. ;

Davids, M. S. .

LEUKEMIA, 2017, 31 (10) :2075-2084

[8] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions [J].

Fischer, K. ;

Al-Sawaf, O. ;

Bahlo, J. ;

Fink, A. -M. ;

Tandon, M. ;

Dixon, M. ;

Robrecht, S. ;

Warburton, S. ;

Humphrey, K. ;

Samoylova, O. ;

Liberati, A. M. ;

Pinilla-Ibarz, J. ;

Opat, S. ;

Sivcheva, L. ;

Du, K. Le ;

Fogliatto, L. M. ;

Niemann, C. U. ;

Weinkove, R. ;

Robinson, S. ;

Kipps, T. J. ;

Boettcher, S. ;

Tausch, E. ;

Humerickhouse, R. ;

Eichhorst, B. ;

Wendtner, C. -M. ;

Langerak, A. W. ;

Kreuzer, K. -A. ;

Ritgen, M. ;

Goede, V. ;

Stilgenbauer, S. ;

Mobasher, M. ;

Hallek, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2225-2236

[9]

FISCHER K, 2019, BLOOD S, V134, DOI DOI 10.1182/BLOOD-2019-125825

[10] Targeting Bruton's tyrosine kinase in B cell malignancies [J].

Hendriks, Rudi W. ;

Yuvaraj, Saravanan ;

Kil, Laurens P. .

NATURE REVIEWS CANCER, 2014, 14 (04) :219-232

← 1 2 3 4 →